Sartorius

Sartorius, a leading international laboratory and biopharmaceutical technology provider headquartered in Germany, is committed to reducing its environmental impact. In 2025, the company reported total carbon emissions of approximately 540 million kg CO2e. This figure comprises about 21.2 million kg CO2e from Scope 1 (direct emissions), approximately 36.0 million kg CO2e from Scope 2 (indirect emissions from purchased energy, using market-based accounting), and around 482.7 million kg CO2e from Scope 3 (value chain emissions).

For 2024, Sartorius's total emissions were approximately 526.2 million kg CO2e, with Scope 1 at roughly 20.4 million kg CO2e, Scope 2 at about 34.8 million kg CO2e (market-based), and Scope 3 at approximately 471.0 million kg CO2e. In 2023, total emissions were around 896.9 million kg CO2e, including Scope 1 at about 13.1 million kg CO2e, Scope 2 at approximately 26.8 million kg CO2e (market-based), and Scope 3 at a substantial 857.0 million kg CO2e.

Sartorius has set ambitious climate targets, aiming for net-zero greenhouse gas emissions by 2045 across its entire value chain. Near-term goals include reducing avoidable Scope 1 and market-based Scope 2 GHG emissions to zero by 2030. The company also targets a 42.0% reduction in absolute Scope 1 and Scope 2 GHG emissions by 2030, using 2022 as a base year. Furthermore, Sartorius aims to reduce its Scope 3 emissions by 51.6% per EUR value added by 2030, also based on 2022 data. These targets are aligned with the Science Based Targets initiative (SBTi) and are considered consistent with limiting warming to 1.5°C.